The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma

Adjuvant and neoadjuvant therapies that reduce the risk of renal cell carcinoma (RCC) recurrence remain an area of unmet need. Advances have been made in metastatic RCC recently by leveraging PD-1/PD-L1 immune checkpoint inhibitors (ICIs). These agents are currently being investigated in the adjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Dibajnia, Pooya, Cardenas, Luisa M., Lalani, Aly-Khan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026863/
https://www.ncbi.nlm.nih.gov/pubmed/36775257
http://dx.doi.org/10.1080/21645515.2023.2178217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026863/
https://www.ncbi.nlm.nih.gov/pubmed/36775257
http://dx.doi.org/10.1080/21645515.2023.2178217

Ejemplares similares